The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. In the United States, most of these compounds are not FDA-approved and are sold for laboratory research only; a few are prescription drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
First published in 2017, it disrupts the FOXO4–p53 interaction to trigger apoptosis selectively in senescent cells – an elegant mechanism that made headlines when treated mice showed restored organ function. As of mid-2026 there are no completed or registered human trials; every result comes from mouse models and cell culture.
